thalidomide has been researched along with Atypical Lipomatous Tumor in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Y | 1 |
Xu, L | 1 |
Mayakonda, A | 1 |
Huang, ML | 1 |
Kanojia, D | 1 |
Tan, TZ | 1 |
Dakle, P | 1 |
Lin, RY | 1 |
Ke, XY | 1 |
Said, JW | 1 |
Chen, J | 1 |
Gery, S | 1 |
Ding, LW | 1 |
Jiang, YY | 1 |
Pang, A | 1 |
Puhaindran, ME | 1 |
Goh, BC | 1 |
Koeffler, HP | 1 |
1 other study available for thalidomide and Atypical Lipomatous Tumor
Article | Year |
---|---|
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.
Topics: Animals; Azepines; Base Sequence; Carcinogenesis; Cell Line, Tumor; Enhancer Elements, Genetic; Geno | 2019 |